Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Hematologic malignancies Clinical Trials

Protocol Number Title
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
COG ALTE05N1 Umbrella Long-Term Follow-Up Protocol
Childhood Cancer Survivor Study
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders From Digital Upgrade to Digital Revolution: A New Era in Survivor Research
MT2012-01 : A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies BMT CTN PROTOCOL 1101
MT2013-03R Impact Of Gender And Frailty On Hematopoietic Cell Transplant
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
HM2013-24: Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
BMT Long-Term Follow-up Study -2
MT2013-06C : Treatment of graft Failure after HSCT
MT2013-09C : Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
Family-based studies of susceptibility to early onset disease
COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
COG AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults "AHOD1331 ? Seattle Genetics"
HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
MT2015-17C :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
MT2015-32C : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
An advance care planning intervention for adolescent and young adult patients undergoing bone marrow transplant
COG ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial Additional Title: NIH Grant 1R01CA196854: ALTE1621
MT2016-13 :A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (CTN 1501)
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
MT2016-33 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease (cGVHD)
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
MT2016-10: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
MT2016-31 A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
MT2016-11C: Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
MT2017-11R The Role of Gut Microbiota in Conditioning-Induced Intestinal Barrier Damage in Patients Undergoing Stem Cell Transplantation
HM2017-21 The Role of Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction Chemotherapy
Building Evidence for Effective Palliative/End of Life Care for Teens with Cancer: FAmily CEntered (FACE) ACP for Teens with Cancer - A multi-site Randomized Control Trial (RCT)
The Development of Limb Position Sense during Childhood
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)

39 trials displayed